Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Jubilant Cadista...

    Jubilant Cadista Pharma recalls over 46,000 bottles of hypertension drug from US

    Written by Ruby Khatun Khatun Published On 2018-09-04T10:30:22+05:30  |  Updated On 4 Sept 2018 10:30 AM IST
    Jubilant Cadista Pharma recalls over 46,000 bottles of hypertension drug from US

    New Delhi: Jubilant Cadista Pharmaceuticals Inc is recalling over 46,000 bottles of Valsartan tablets manufactured by Jubilant Generics Ltd at its Roorkee plant from the American market, the latest Enforcement Report of the US health regulator has said.


    Valsartan tablets are used for the treatment of hypertension and heart failure.


    The company is recalling 10,577 bottles of Valsartan tablets USP in the strength of 40 mg, 9,552 bottles of the 80 mg tablets, 18,947 bottles of 160 mg tablets and 7,048 bottles of 320 mg tablets, the report added.

    The tablets are being recalled on account of "Incorrect/Undeclared excipient: There is a potential an incorrect grade of excipient was used during manufacturing," it added.

    The voluntary, ongoing recall is a class III recall, the report by the United States Food and Drug Administration (USFDA) said.

    The product was distributed throughout the United States to wholesalers and retailers, it added.

    As per USFDA, a class III recall is initiated in a situation, "in which use of or exposure to a violative product is not likely to cause adverse health consequences."
    American marketbottlesclass III recallEnforcement Reportheart failurehypertensionhypertension drugJubilantJubilant Cadista PharmaJubilant Generics LtdrecallrecallingrecallsRoorkee plantUnited States Food and Drug AdministrationUSUSFDAValsartan Tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok